Bio-Techne Corp [TECH] stock is trading at $51.40, up 3.05%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The TECH shares have gain 5.37% over the last week, with a monthly amount glided 2.92%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Bio-Techne Corp [NASDAQ: TECH] stock has seen the most recent analyst activity on May 30, 2025, when Wells Fargo initiated its Overweight rating and assigned the stock a price target of $59. Previously, KeyBanc Capital Markets downgraded its rating to Sector Weight on April 09, 2025. On March 18, 2025, Evercore ISI initiated with a Outperform rating and assigned a price target of $75 on the stock. Robert W. Baird downgraded its rating to a Neutral and decreased its price target to $68 on February 19, 2025. Citigroup downgraded its rating to a Neutral but $85 remained the price target by the analyst firm on May 22, 2024. Scotiabank started tracking with a Sector Outperform rating for this stock on February 08, 2024, and assigned it a price target of $80. In a note dated February 02, 2024, Stifel downgraded an Hold rating on this stock but restated the target price of $65.
Bio-Techne Corp [TECH] stock has fluctuated between $46.01 and $83.62 over the past year. Currently, Wall Street analysts expect the stock to reach $75 within the next 12 months. Bio-Techne Corp [NASDAQ: TECH] shares were valued at $51.40 at the most recent close of the market. An investor can expect a potential return of 45.91% based on the average TECH price forecast.
Analyzing the TECH fundamentals
Bio-Techne Corp [NASDAQ:TECH] reported sales of 1.21B for the trailing twelve months, which represents a growth of 4.20%. Gross Profit Margin for this corporation currently stands at 0.66% with Operating Profit Margin at 0.17%, Pretax Profit Margin comes in at 0.13%, and Net Profit Margin reading is 0.11%. To continue investigating profitability, this company’s Return on Assets is posted at 0.05, Equity is 0.06 and Total Capital is 0.08. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.21.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
For context, Bio-Techne Corp’s Current Ratio is 3.71. As well, the Quick Ratio is 2.58, while the Cash Ratio is 0.83. Considering the valuation of this stock, the price to sales ratio is 6.67, the price to book ratio is 3.99 and price to earnings (TTM) ratio is 62.65.
Transactions by insiders
Recent insider trading involved JOSHUA MOLHO, Officer, that happened on Jun 09 ’25 when 1280.0 shares were purchased. Director, Herr Amy E. completed a deal on Feb 14 ’25 to sell 1860.0 shares. Meanwhile, Domestic Partner of Director JOSHUA MOLHO bought 1860.0 shares on Feb 14 ’25.
